Adam Houldsworth

Content from this author

• Meet this year’s IP Hall of Fame inductees - Brian Hinman
• Meet this year’s IP Hall of Fame inductees - Margaret ‘Meg’ Boulware
• Meet this year’s IP Hall of Fame inductees - Dale Cendali
• Meet this year’s IP Hall of Fame inductees - Lionel Bently K.C.
• 10x Genomics strikes blow against NanoString in the US
• $227 million Apollo Therapeutics investment is a major boost for innovative tech transfer approach
• Oppo injuncted after refusing to accept UK court's global FRAND rate
• RegenxBio/Sarepta dispute highlights strategic challenges for gene therapy developers
• UPC holds first ever preliminary injunction hearing
• Janssen secures yet more patent settlements with Stelara biosimilars
• Unitary Patents increasingly popular with Asian innovators
• US appeal court antitrust decision is good news for patent licensing
• Moderna jab does not infringe Alnylam mRNA patents, finds US court
• Gucci sued at the UPC – five key takeaways
• Oppo counteroffensive against Nokia suffers another EPO setback
• ‘We want to de-risk the CRISPR-Cas9 patent minefield’, says Sigma-Aldrich IP licensing boss
• UPC faces first bifurcation challenge in Amgen v Sanofi/Regeneron spat
• Avanci signs up first new Broadcast licensees
• UPC schedules its first substantive hearings
• UPC case data reveals dominance of German IP professionals and firms
• We are seeking CRISPR IP partnerships, says SNIPR Biome’s chief patent counsel
• BREAKING: Avanci launches 5G programme with Huawei on board, and Mercedes-Benz as first licensee
• European Parliament makes crucial appointment to handle controversial SEP proposals
• Novartis’ Gilenya woes deepen as Dusseldorf court overturns preliminary injunction
• More UPC transparency is needed to make the most of its potential
• IAM insight panel analysis H1 2023
  Featured in Community Insight
• Patent litigation funding at risk in wake of UK Supreme Court ruling
• nChain's $570 million investment reflects value of its IP, CSO says
• UPC lawsuits dominated by Europe-based corporations and SMEs
• Bristol-Myers’ $560 million settlement is yet another success for its patent licensing campaign
• Panasonic files wave of UPC lawsuits against Oppo and Xiaomi
• Delaware landmark preliminary injunction dismissal is bad news for biologics patentees
• Mylan off the hook for $50 million tax bill for patent expenses
• $7 billion Roivant deal would be ultimate vindication of its pioneering IP commercialisation model
• IAM’s top takeaways from IPBC Global 2023
• Nokia wins UK willingness decision, while Oppo terminates French distribution
• European innovators embrace the Unitary Patent
• Ocado gets £200 million in ‘robot wars’ settlement after turning the tables on AutoStore
• Genentech sues Biogen as new wave of biosimilars disputes grows
• Avanci announces first new Aftermarket licensee since launch
• Apple catch-up royalty payments help Nokia mitigate economic headwinds
• CRISPR patent interference overturned by Federal Circuit
• UPC adds to need for EPO patent quality improvement, says Siemens’ IP chief
• Humira interchangeable launches will send important signals for patent strategy
• UPC looks set for first antitrust spat in unusual life sciences dispute
• Ericsson’s patent strategy is evolving, says VP of global licensing
• Apple voting rights expansion triggers 3GPP rule change
• Moderna files Irish lawsuit against Pfizer/BioNTech in ever-expanding covid dispute
• Huawei files UPC suit to ramp up pressure in Netgear SEP dispute
• How life sciences companies are embracing the UPC

• Nokia and Apple ink major, new 5G SEP licence without need for litigation
• Nokia lands blow against Oppo as developments continue apace in global patent dispute
• InterDigital to appeal UK FRAND decision while Lenovo battle continues in China and US
• Enlarged Board of Appeal’s landmark ‘plausibility’ ruling creates new uncertainties
• Amgen continues to write biosimilars IP playbook with first-to-market Stelara settlement
• Oppo boosted in patent counter-offensive against Nokia
• UPC’s early cases suggest Munich becoming the focal point of European patent litigation
• The fightback against the European Commission’s SEP proposals shifts up a gear
• China, IP finance and trade secrets top the bill at IPBC Global day two
• Lessons from IP leadership on day one of IPBC Global 2023
• Nokia’s battles with Oppo and Vivo underscore the UPC/UP’s importance for SEP owners
• UPC week one in six key takeaways
• Optis suffers major defeat in English High Court global FRAND rate decision
• First unitary patent assertion occurs on UPC day one, as 10x Genomics follows up on German success
• New frontiers of life sciences IP strategy are posing challenges for patent professionals
• UPC launch is a pivotal moment for European and global patent strategy
• Ravgen assertion campaign highlights problems with US patent reforms
• UPC conflict rules place heavy burden on part-time judges
• IP Hall of Fame inductees for 2023 revealed
• Five key takeaways from SCOTUS’ landmark Amgen v Sanofi enablement ruling
• UPC central division will have branch in Milan, Italian government announces
• German court issues first ever AASI in life sciences case
• SCOTUS turns down much-watched ‘skinny label’ appeal in blow to generic drug companies
• UPC system experiencing severe problems as patentees race to opt out their rights
• It is time for life sciences IP professionals to embrace change in the industry
• Biogen’s European exclusivity boost is silver lining following US Tecfidera disaster
• Gilead scores major victory in controversial $1 billion dispute with US government
• The EU’s new proposal throws up new IP challenges for AI data mining
• Amgen sues Sandoz as new wave of biosimilars disputes gains momentum
• Qualcomm licensing woes deepened by ongoing handset headwinds
• Moderna’s ongoing struggles over covid infringement liability have broader implications
• European Commission proposes unitary SPC as part of mixed bag of pharma IP reforms
• Commissioner Breton takes aim at “bad faith” patent licensors as final SEP policy proposal released
• Ravgen continues winning streak in big-money patent assertion campaign
• New draft European Commission SEP regulation shows tweaks but no rewrite
• Amgen’s Federal Circuit victory vindicates $13.4 billion Otezla IP acquisition
• The European Commission’s SEP regulation would be a geostrategic liability for the EU
• Patent cliff concerns drive Merck’s $11 billion Prometheus buyout
• BREAKING: Avanci signs Samsung to 2G-4G SEP platform as a licensor
• Ocado IP chief says company is now on the offensive in AutoStore dispute following UK victory
• IPBC Europe day two key highlights
• Bristol-Myers Squibb and Dana-Farber settle landmark dispute
• Nokia wins German injunction against Vivo, mirroring Oppo dispute
• New Pfizer/BioNTech covid-19 lawsuit adds to complex web of mRNA disputes
• IP Hall of Fame: Last chance to nominate
• The EU is worryingly ambivalent about IP
• SEP/FRAND policy is about finding the middle ground, says UKIPO CEO
• Ericsson win in India cements country as a go-to SEP litigation venue
• Nokia’s Oppo/Vivo lawsuits were a false start for Indonesian SEP/FRAND litigation
• SEP owners have a big fight on their hands to evade radical new EU regulation